Cardiovascular outcomes and mortality in diabetic multiple myeloma patients initiated on proteasome inhibitors according to prior use of glucagon-like peptide 1 agonists - Top-Institutions - MDSpire

Cardiovascular outcomes and mortality in diabetic multiple myeloma patients initiated on proteasome inhibitors according to prior use of glucagon-like peptide 1 agonists

  • By

  • Yu-Cheng Chang

  • Chun-Yu Peng

  • Kuan-Yu Chi

  • Junmin Song

  • Yu Chang

  • Cho-Hung Chiang

  • Wenli Gao

  • Cho-Han Chiang

  • January 29, 2025

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology-Oncology
    • Cardiology
    • Endocrinology

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology-Oncology
    • Cardio-Oncology
    • Endocrinology

  • #3

    Johns Hopkins Medicine
    Johns Hopkins Medicine

    Baltimore, MD

    Key Differentiators

    • Hematology-Oncology
    • Cardiology
    • Endocrinology

  • #4

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology-Oncology
    • Cardio-Oncology
    • Endocrinology

  • #5

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Cardiology
    • Hematology-Oncology
    • Endocrinology

Original Source(s)

Cardiovascular outcomes and mortality in diabetic multiple myeloma patients initiated on proteasome inhibitors according to prior use of glucagon-like peptide 1 agonists

  • by Yu-Cheng Chang, Chun-Yu Peng, Kuan-Yu Chi, Junmin Song, Yu Chang, Cho-Hung Chiang, Wenli Gao, Cho-Han Chiang

  • January 29, 2025

Related Content

Impact of Previous Cardiac Surgery on Outcomes After Tricuspid Valve Transcatheter Edge-to-Edge Repair: Insights from EuroTR

Correction: Association between systemic immune-inflammation index(SII) and all-cause and cardiovascular mortality in heart failure patients: a single-center retrospective analysis

Retinal Age as Disease Biomarker

Fundus-based AI screening can indicate “retinal age” of patients, as well as flag systemic disease risks, says new study

  • May 27, 2026

  • 3 min